Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced
today that the original target of 400 subjects for its Canadian Phase
III psoriasis trial for its lead immunosuppressive compound, ISA247
has been reached. Due to the enthusiasm of our investigators and the
willingness of patients to participate in the trial, the Company will
allow approximately 80 additional patients to receive drug treatment.
Total enrolment for the trial will therefore be approximately 480
The trial, which commenced on December 2, 2004, is currently being
conducted at thirty-two centres across Canada and involves patients
with moderate to severe psoriasis. Patients have been randomised to
one of the four dosing arms; high dose (0.4 mg/kg twice daily), mid
dose (0.3 mg/kg twice daily), low dose (0.2 mg/kg twice daily) and
placebo. Subsequent to the first 12 weeks, those patients who
received placebo will be administered the mid dose range dose of 0.3
mg/kg twice daily for the remaining 12 weeks of the study.
"Our willingness to allow additional subjects into the trial was
based on numerous requests received from our investigators and those
patients suffering from psoriasis," stated Dr. Randall Yatscoff,
Isotechnika's President and Chief Operating Officer. "Requests to
allow for additional psoriasis patients to be added to the trial
likely speak to the unmet medical need of trying to find safer and
efficacious drug therapies. The Company anticipates release of
interim results, which is based on 300 patients completing the first
twelve weeks of treatment, to the investment and scientific community
in the third quarter of 2005 with final results expected in early
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead drug, ISA247, presently referred to as
trans-ISA247, is an immunosuppressant that has successfully completed
a Phase II trial for psoriasis and Phase IIa trial for kidney
transplantation. The Company also has two additional
immunosuppressive compounds in its drug pipeline, TAFA93 and TKB662.
Both compounds are in early stage clinical development, Phase I and
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(TM) and Diatest(TM)
breath kits. The Helikit(TM), a (13)C breath test is used for the
detection of H.pylori, a bacterium that infects a large portion of
the population. The Diatest(TM), a (13)C glucose breath test is used
to measure insulin resistance.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward- looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialise its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.newsaktuell.ch
Dr. Randall Yatscoff, President & COO, Isotechnika Inc., Phone:
+1-780-487-1600 Ext.246, Fax: +1-780-484-4105, Email:
email@example.com; Stephanie Gillis-Paulgaard, Senior
Manager, Corporate Communications & Investor Relations, Isotechnika
Inc., Phone: +1-780-487-1600 Ext. 243, Fax: +1-780-484-4105, E-mail: